Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

HNRNPA2B1 regulates tamoxifen- and fulvestrant-sensitivity and hallmarks of endocrine resistance in breast cancer cells

Cancer Letters(2021)10.1016/j.canlet.2021.07.015Source: DataRank Database

HNRNPA2B1 regulates tamoxifen- and fulvestrant-sensitivity and hallmarks of endocrine resistance in breast cancer cells is a research paper published in Cancer Letters (2021). On theSindex it has a DataRank of 0. It has been cited 74 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access74 citations

Download PDF

Cite:

Linked data & code

geo doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 4.74)OA: greenTopics (31)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Kellianne M. Piell ORCID,Gordon C. South Whitt,Ali E. Wilt,Claire C. Poulton,Norman L. Lehman ORCID

Live enrichment

PubMed:34273466 PMC:PMC8358706 OpenAlex:https://openalex.org/W3178965203

National Institutes of Health

Grant: R21CA212952

National Institutes of Health

Grant: R25 CA134283

National Institutes of Health

Grant: T32 ES011564

National Institutes of Health

Grant: T35 DK072923

NINDS NIH HHS

Grant: R01 NS081125

NCI NIH HHS

Grant: R21 CA219252

NIGMS NIH HHS

Grant: P30 GM127607

FWCI

4.74

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8358706

publisherhttps://api.elsevier.com/content/article/PII:S0304383521003426?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0304383521003426?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.canlet.2021.07.015

Fields of Study

RNA modifications and cancerRNA Research and SplicingRNA regulation and disease

MeSH Terms

FulvestrantAdenosineBreast NeoplasmsFemaleHumansTamoxifenNeoplastic Stem CellsSignal TransductionHyaluronan ReceptorsHeterogeneous-Nuclear Ribonucleoprotein Group A-BCell Line, TumorEstrogen Receptor alphaCD24 AntigenEndocrine CellsMCF-7 Cells

Keywords

FulvestrantBreast cancerGene knockdownTamoxifenCancer researchBiologyCancerInternal medicineMedicineCell cultureGeneticsEREndocrine Resistance

Sustainable Development Goals

SDG 0: Good health and well-being